ANIK
Anika Therapeutics Inc
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Best Medical Devices Stocks 2026 →
Anika Therapeutics (ANIK) Stock: Buy, Sell, or Hold?
$13.95
+0.48 (+3.56%)
▲
5d:
-31.62%
30d:
-32.05%
90d:
-34.1%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 06, 2026
0d
Protect ANIK Gains
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (72%)
Quality Score
46/100
Position
OVERSOLD
30-Day Fair Range
$17.16 – $21.76
Position: OVERSOLD
Forward P/E & Valuation
73.4x
STRETCHED
vs 31.4x historical avg
Wall Street Target
$23.00
+64.9% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$13.33 / $21.85
Trend: Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: ANIK is down 31.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Get Alerted When ANIK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: ANIK is currently trading at $13.95, which is considered oversold relative to its 30-day fair value range of $17.16 to $21.76. From a valuation perspective, the stock is trading at a premium (Forward PE: 73.4) compared to its historical average (31.4). At these levels, the market is pricing in 32.7% annual earnings growth.
Technical Outlook: Technically, ANIK is in a uptrend. Immediate support is located at $13.33, while resistance sits at $21.85. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: ANIK scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $23.00 (+64.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ANIK is in a uptrend. Immediate support is located at $13.33, while resistance sits at $21.85. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: ANIK scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $23.00 (+64.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$17.16 -
$21.76
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
71.9%
Trading Range & Key Levels
30-Day Trading Range
$17.16 -
$21.76
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.74
(5.3%)
Support Level
$13.33
Resistance Level
$21.85
Current Trend
Uptrend
Technical data as of
Nov 11, 2026
Protect Your Profits
Holding ANIK? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.6%)
- BULLISH: Trading 64.9% below Wall St target ($23.00)
- BULLISH: Expecting earnings turnaround to 32.7% growth with 10.0% revenue growth
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
73.42
Wall Street Target
$23.00
(+64.9%)
Revenue Growth (YoY)
10.0%
Earnings Growth (YoY)
-50.5%
Profit Margin
-1.4%
Valuation Premium vs History
+32.7% premium
PE vs Historical
73.4 vs 31.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+32.7%
(market-implied from PE analysis)
1-Year Target
$18.51
(+33%)
2-Year Target
$24.56
(+76%)
3-Year Target
$32.60
(+134%)
3-Yr Target (if PE normalizes)
(PE: 73→31)
PE COMPRESSION
$13.94
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 73.4, Growth: 90.0%)
$47.08
(+238%)
Base:
(SPY PE: 19.9, Growth: 90.0%)
$12.74
(-9%)
Bear:
(PE: 16.9, Growth: 90.0%)
$10.82
(-22%)
Share ANIK Analysis
Share this live ANIK analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (ANIK)
Bearish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 6, 2026
Daily AI digest
AI Retail Discussion Summary:
Anika Therapeutics reported Q3 revenue growth and raised revenue forecasts, but lowered commercial growth outlook due to slower U.S. elective surgery activity. FDA found Hyalofast premarket approval application not approvable.
Key Retail Themes:
revenue growth
regulatory issues
product developments
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 3:34 AM ET
Data refreshes hourly during market hours. Next update: 4:34 AM
Data refreshes hourly during market hours. Next update: 4:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANIK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 33 SELL |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$687 | 52 HOLD |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 53 HOLD |
Advanced ANIK Option Strategies
Professional options setups generated by AI based on today's ANIK price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive ANIK Research Pages
